Overview

* Marker Q3 net loss narrows to $2 mln from $2.3 mln yr/yr

* MT-601 shows 66% response rate in relapsed NHL patients

* Company raises $10 mln through ATM facility, extending cash runway into 2026

Outlook

* Marker plans to share additional MT-601 data in the first half of 2026

* Company focuses on enrolling patients in MT-601 dose expansion cohort

* Marker's cash runway extended into 2026 through recent fundraising

Result Drivers

* R&D - Expenses were $2.3 million for the quarter ended September 30, 2025, compared to $3.5 million for the quarter ended September 30, 2024

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 EPS -$0.12

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the biotechnology & medical research peer group is "buy"

* Wall Street's median 12-month price target for Marker Therapeutics Inc ( MRKR ) is $8.00, about 88.9% above its November 13 closing price of $0.89

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)